Otsuka Bags Novel Antibody Tech, Pipeline In $430m Visterra Buy

 
• By Ian Haydock

Otsuka liked the private US antibody tech company Visterra so much that it is buying it, in a move developing out of licensing discussions and which the Japanese firm says will strengthen its presence in biologics for renal disorders and other high-need areas.

Human antibody
OTSUKA BUILDS ANTIBODY EXPERTISE THROUGH VISTERRA PURCHASE • Source: Shutterstock

More from Deals

More from Business